scPharmaceuticals, Inc.

As of May 10, 2023, scPharmaceuticals, Inc. is classified as risky and appears overvalued due to negative valuation ratios, despite a year-to-date return of 58.76% that outperforms the S&P 500's 12.22%.

As of May 10, 2023, scPharmaceuticals, Inc. is considered a risky investment due to its negative financial ratios and underperformance compared to peers, with a 1-year return of -4.96% versus the S&P 500's 10.26%.

As of June 13, 2025, the market trend is mildly bearish, indicated by daily moving averages and Dow Theory, despite mixed signals from MACD and Bollinger Bands across different timeframes.

As of March 2022, the management team of scPharmaceuticals, Inc. includes Independent Chairman Mr. Jack Khattar, President and CEO Mr. John Tucker, and several Independent Directors: Ms. Mette Agger, Ms. Minnie Baylor-Henry, Ms. Sara Bonstein, Dr. Mason Freeman, and Mr. Frederick Hudson. This team provides executive leadership and governance for the company.

scPharmaceuticals, Inc. is a biopharmaceutical company focused on developing products for subcutaneous delivery, with a market cap of approximately $210.64 million and recent net sales of $12 million, but a net loss of $20 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

As of Jun 18, scPharmaceuticals, Inc. has a market capitalization of 210.64 million and reported net sales of 41.98 million, with a net profit loss of 90.77 million over the latest four quarters. The company has shareholder's funds of 13.32 million and total assets of 107.52 million.